Corporate Site
Skip to main content
Please note: Quidel’s new Corporate Headquarters address is 9975 Summers Ridge Road, San Diego, CA 92121.

News Releases

Corporate Site
Press Release RSS Feed (opens in new window)
Press release year list 2020 2019 2018 2017 2016 2015 2014
08/27/2020
Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy
08/27/2020
Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour
08/20/2020
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
08/19/2020
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
08/10/2020
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
07/31/2020
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
07/30/2020
Quidel Reports Second Quarter 2020 Financial Results
07/29/2020
Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
07/17/2020
Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments
07/13/2020
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
07/06/2020
Quidel Announces Preliminary Revenue for Second Quarter 2020
06/11/2020
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
06/11/2020
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
06/09/2020
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
05/26/2020
Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
05/18/2020
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
05/08/2020
Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay
05/06/2020
Quidel Reports First Quarter 2020 Financial Results
04/29/2020
Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference
04/22/2020
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
04/21/2020
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
03/25/2020
Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization
03/17/2020
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
02/18/2020
Quidel to Present at Upcoming Conferences
02/12/2020
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
01/28/2020
Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020
01/09/2020
Quidel Announces Preliminary Revenue for Fourth Quarter 2019